Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05220917 · ClinicalTrials.gov registry record
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
A clinical trial of Type 2 Diabetes and Renal Disease, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- 781,430
- Enrollment target
- 1
- Study location
NCT05220917: Active study of Type 2 Diabetes and Renal Disease, sponsored by Brigham and Women's Hospital.
NCT05220917 is a study of Type 2 Diabetes and Renal Disease that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 781,430 participants, above the 1,534-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (50841% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05220917, a study of Type 2 Diabetes and Renal Disease, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 781,430 participants
- Enrollment target
- 1
- Study location
Study Summary
To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i), and sulfonylureas (SU), at the class and individual agent level, in head-to-head comparisons in patients with type 2 diabetes (T2D).
Primary Outcome
Myocardial Infarction, Ischemic Stroke, Cardiovascular mortality
Conditions Studied
Interventions
- DRUG SGLT2 inhibitor
- DRUG DPP-4 inhibitor
- DRUG GLP-1RA
- DRUG 2nd generation SU
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 781,430 participants |
| Start Date | 2021-08-01 |
| Est. Completion | 2026-07-01 |
What the registry record for NCT05220917 still lists
NCT05220917 is an observational study that tracks outcomes without assigning an intervention. Its 781,430 participants enrollment target places it among the larger protocols in the corpus, above the 1,534-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (50841% higher).
The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 4 interventions - of which SGLT2 inhibitor is the first listed.
NCT05220917 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05220917 about?
NCT05220917 is a clinical study titled "Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study". To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-...
What is the current status of trial NCT05220917?
This trial is currently active not recruiting. The enrollment target is 781,430 participants. The study started on 2021-08-01. Estimated completion is 2026-07-01.
What conditions does trial NCT05220917 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Renal Disease, Cardiovascular Events.
What interventions are being tested in trial NCT05220917?
The interventions under investigation include: SGLT2 inhibitor (DRUG), DPP-4 inhibitor (DRUG), GLP-1RA (DRUG), 2nd generation SU (DRUG).
Who is sponsoring clinical trial NCT05220917?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05220917 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05220917's enrollment target sits among peer trials
781,430 1st of 327 higher than 327 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01073475 · 950,000 participants
Maternal Newborn Health Registry
- NCT06029933 · 960,000 participants
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
- NCT05066763 · 1,000,000 participants
Parkinson's Foundation Surveys
- NCT07075341 · 1,000,000 participants
Healthy Living BEYOND Weight Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI